In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

Weeks after bowing out of a billion-dollar deal with Aduro Biotech, J&J is back to the drawing board with another oncology licensing pact that, if fruitful, could pit them directly against AstraZeneca’s lung cancer star Tagrisso.